Favorite  |  Set Home
Products > PI3K/Akt/mTOR > PI3K > GDC-0032
Product name : GDC-0032
Item : CR1936
Price : 200mg, $950;500mg, $1695; 1g, $2490; 2g, $3590
contact : Send inquiry to: info@acesobio.com
CAS : 1282512-48-4
Molecular Weight : 460.53
Formula : C₂₄H₂₈N₈O₂
Storage : at -20°C
Additional information : We offer significant discount for bulky quantity order
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Details:
 

Chemical Information

M.Wt 460.53 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C24H28N8O2
CAS No 1282512-48-4
Solubility

DMSO



Biological Activity of GDC-0032

 

GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

IC50 Value: 0.29 nM/0.12 nM /0.97 nM(PI3Kα/δ/γ) [1]

Target: PI3K

in vitro: GDC-0032 is an orally bioavailable, potent, and selective inhibitor of Class I PI3Kα, δ, and γ isoforms, with 30 fold less inhibition of the PI3K β isoform relative to the PI3Kα isoform. Preclinical data show that GDC-0032 has increased activity against PI3Kα isoform (PIK3CA) mutant and HER2-amplified cancer cell lines. GDC-0032 inhibits MCF7-neo/HER2 cells proliferation with IC50 of 2.5 nM.

in vivo: GDC-0032 pharmacokinetics is approximately dose proportional and time independent with a mean t1/2 of 40 hours. The combination of GDC-0032 enhances activity of fulvestrant resulting in tumor regressions and tumor growth delay (91% tumor growth inhibition (TGI)). In addition, the combination of GDC-0032 with tamoxifen enhances the efficacy of tamoxifen in vivo (102%TGI for GDC-0032) [1].

 

Clinical Information of GDC-0032

MORE

[1]. Ndubaku CO, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 Jun 13;56(11):4597-610.
Abstract
Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, we observed a strong dependency of in vivo antitumor activity on the free-drug exposure. By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compounds that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels. One of these compounds, GDC-0032 (11l), was progressed to clinical trials and is currently under phase I evaluation as a potential treatment for human malignancies.


Related Products :
CH 5132799
CH 5132799
Price: 200mg, $1250;500mg, $2090; 1g $2995; 2g, $4395
PIK 293
PIK 293
Price: 200mg, $950;500mg, $1595; 1g $2390; 2g, $3590
AS 604850
AS 604850
Price: 200mg, $1250;500mg, $2090; 1g $2995; 2g, $4395
PIK 294
PIK 294
Price: 200mg, $950;500mg, $1595; 1g $2390; 2g, $3590
GSK 1059615
GSK 1059615
Price: 200mg, $950;500mg, $1595; 1g $2390; 2g, $3590
Palomid 529 (P529)
Palomid 529 (P529)
Price: 200mg, $750;500mg, $1190; 1g $1890; 2g, $2995
GDC 0980 (RG7422)
GDC 0980 (RG7422)
Price: 200mg, $750;500mg, $1250; 1g $1950; 2g, $3050
NVP-BGT226 (BGT 226)
NVP-BGT226 (BGT 226)
Price: 200mg, $950;500mg, $1650; 1g $2450; 2g, $3650